Skip NavigationSkip to Content

Antiviral activity of alpha-helical stapled peptides designed from the HIV-1 capsid dimerization domain

  1. Author:
    Zhang, H. T.
    Curreli, F.
    Zhang, X. H.
    Bhattacharya, S.
    Waheed, A. A.
    Cooper, A.
    Cowburn, D.
    Freed, E. O.
    Debnath, A. K.
  2. Author Address

    [Zhang, HT; Curreli, F; Zhang, XH; Debnath, AK] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Mol Modeling & Drug Design, New York, NY 10065 USA [Bhattacharya, S] New York Struct Biol Ctr, New York, NY 10027 USA [Waheed, AA; Freed, EO] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Frederick, MD 21702 USA [Cooper, A] Univ Glasgow, Sch Chem, Glasgow G12 8QQ, Lanark, Scotland [Cowburn, D] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY 10461 USA;Debnath, AK (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Mol Modeling & Drug Design, 310 E 67th St, New York, NY 10065 USA;adebnath@nybloodcenter.org
    1. Year: 2011
    2. Date: May
  1. Journal: Retrovirology
    1. 8
    2. Pages: 18
  2. Type of Article: Article
  3. Article Number: 28
  4. ISSN: 1742-4690
  1. Abstract:

    Background: The C-terminal domain (CTD) of HIV-1 capsid (CA), like full-length CA, forms dimers in solution and CTD dimerization is a major driving force in Gag assembly and maturation. Mutations of the residues at the CTD dimer interface impair virus assembly and render the virus non-infectious. Therefore, the CTD represents a potential target for designing anti-HIV-1 drugs. Results: Due to the pivotal role of the dimer interface, we reasoned that peptides from the alpha-helical region of the dimer interface might be effective as decoys to prevent CTD dimer formation. However, these small peptides do not have any structure in solution and they do not penetrate cells. Therefore, we used the hydrocarbon stapling technique to stabilize the alpha-helical structure and confirmed by confocal microscopy that this modification also made these peptides cell-penetrating. We also confirmed by using isothermal titration calorimetry (ITC), sedimentation equilibrium and NMR that these peptides indeed disrupt dimer formation. In in vitro assembly assays, the peptides inhibited mature-like virus particle formation and specifically inhibited HIV-1 production in cell-based assays. These peptides also showed potent antiviral activity against a large panel of laboratory-adapted and primary isolates, including viral strains resistant to inhibitors of reverse transcriptase and protease. Conclusions: These preliminary data serve as the foundation for designing small, stable, alpha-helical peptides and small-molecule inhibitors targeted against the CTD dimer interface. The observation that relatively weak CA binders, such as NYAD-201 and NYAD-202, showed specificity and are able to disrupt the CTD dimer is encouraging for further exploration of a much broader class of antiviral compounds targeting CA. We cannot exclude the possibility that the CA-based peptides described here could elicit additional effects on virus replication not directly linked to their ability to bind CA-CTD.

    See More

External Sources

  1. DOI: 10.1186/1742-4690-8-28
  2. WOS: 000290730000001

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel